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Considerable variation is evident in response to psychological therapies for mood and anxiety disorders. Genetic
factors alongside environmental variables and gene-environment interactions are implicated in the etiology of
these disorders and it is plausible that these same factors may also be important in predicting individual differences
in response to psychological treatment. In this article, we review the evidence that genetic variation influences
psychological treatment outcomes with a primary focus on mood and anxiety disorders. Unlike most past work,
which has considered prediction of response to pharmacotherapy, this article reviews recent work in the field of
therapygenetics, namely the role of genes in predicting psychological treatment response. As this is a field in its
infancy, methodological recommendations are made and opportunities for future research are identified.
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Anxiety and depressive disorders are among the most
common disorders with lifetime prevalence estimates of
28.8% for anxiety disorders and 20.8% for mood disor-
ders [1]. They are some of the most disabling conditions
and contribute a significant proportion of the worldwide
burden of disease [2]. Psychotherapeutic approaches are
recommended for the treatment of depression and all
anxiety disorders [3], with the predominant approach
being Cognitive Behaviour Therapy (CBT). In the UK,
up to 10% of adults with anxiety or depression receive
psychological treatments [4].Individual differences in psychological treatment
response
CBT is not universally effective with response varying con-
siderably between patients. While many people experience
positive outcomes of therapy, approximately 35-45% of
individuals retain significant impairments with a small
number getting worse with treatment [5,6]. However, only
limited research has investigated the source of this individ-
ual variation in psychological treatment response despite* Correspondence: kathryn.lester@kcl.ac.uk
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reproduction in any medium, provided the orthe potential of such work to guide treatment selection
and improve outcome. Clinical and demographic charac-
teristics have proven to be relatively weak or inconsistent
predictors of who will respond to psychological treatment.
Several authors have suggested that the most reliable pre-
dictors of response may come from the origins of the dis-
order, that is “cause should inform cure” [7,8].
There is an increasing interest in identifying biomar-
kers, which predict differential treatment response.
These markers can be used to match particular groups
of patients with treatments to which they are more likely
to show a positive response from the outset in an ap-
proach termed “stratified medicine” [9]. Mood and anx-
iety disorders represent suitable therapeutic areas for
stratified medicine to emerge. There is considerable dis-
ease variability probably reflecting multifactorial etiology
or biologically distinct conditions not yet distinguishable
on the basis of clinical presentations. There are also
multiple relevant targets for therapeutic intervention
and multiple treatment options with evidence of hetero-
geneity in response. These factors have been identified
as necessary for the emergence of stratified medicine [9].
The causal pathways to mood and anxiety disorders in-
volve a combination of genetic and environmental risk
factors. Just as the genetic and environmental factorsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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across patients, so does the way that patients respond to
the same treatment. Genetic (and environmental) factors
are very likely to be involved in this differential response
to treatment and thus represent plausible biomarkers.
In this article, we begin by briefly outlining the contri-
bution of genetic, environmental and gene-environment
interactions (G×E) to the etiology of mood and anxiety
disorders. We then consider how the use of “therapeutic
G×E” designs can be used to investigate whether genetic
variants can be used to predict individual differences in
response to positive environmental influences, namely
psychological treatment interventions. We focus on the
new field of “therapygenetics” [10] and review recent re-
search that has investigated genetic predictors of individ-
ual differences in response to psychological therapy for
mood and anxiety disorders. We conclude by outlining
some important methodological considerations and po-
tential developments for future research in this field.Genetic and environmental basis of mood and
anxiety disorders
Mood and anxiety disorders are highly heterogeneous
conditions. There are multiple causal pathways to these
disorders involving various combinations of environmen-
tal and genetic risk factors, which alone are neither neces-
sary nor sufficient for the disorder to develop [11,12].
Psychological illness tends to run in families strongly im-
plicating genetics as a causal factor. This is confirmed by
twin studies, which report that anxiety and mood disor-
ders are moderately heritable [13,14]. While genetic risk
factors do robustly predict onset, they are not a sufficient
cause of these disorders. This is consistent with many
monozygotic twins being concordant for a disorder, while
others, despite their genetic similarity are discordant [15].
Environmental adversity, trauma and stress also often
precede the onset of psychological illness implicating psy-
chosocial factors in the causal pathway for mood and anx-
iety disorders. However, stress alone is not a sufficient
cause: For example, only a minority (~20%) of those
exposed to severe stressful life events (SLEs) go on to ex-
perience an episode of depression [16]. In others, mood
and anxiety disorders emerge independent of recent stress
[17]. This suggests considerable individual variation in the
causal pathways to disease, which is mirrored in response
to treatment: Not all patients will respond in the same
way to the same treatment. Genetic and environmental
factors, just as they are implicated in different etiological
pathways to disorder may also determine individual vari-
ation in treatment response [18]. While this is a reason-
able supposition, it is important to note that as yet there
are no twin studies available that provide heritability esti-
mates of response to psychological therapy [19].Gene-Environment interaction in mood and
anxiety disorders
Genetic and environmental factors do not operate inde-
pendently from each other and instead often co-occur in a
causal pathway to disease within the context of gene-
environment interaction. A G×E interaction occurs when
a genetic and environmental factor participate in the same
causal mechanism in the same individual [20]. For ex-
ample, genetic variation may moderate the effects of the
environment, placing some individuals at increased risk
for disease, while making others resistant to the effects of
negative or stressful environments.
The best-established and replicated G×Es for psycho-
logical disorders are the interaction between a functional
variable number tandem repeat in the monoamine-
oxidase-A gene (MAOA) and childhood maltreatment in
the onset of antisocial and violent behaviour [21,22] and
the interaction between the serotonin transporter gene
functional length polymorphism (5HTTLPR) and child-
hood maltreatment in the etiology of depression [23,24].
Males carrying the low expression short alleles of the
MAOA-u VNTR and with a history of childhood maltreat-
ment have a greater risk for antisocial behaviour. However,
the association between childhood maltreatment and anti-
social behaviour is weak in those carrying the high expres-
sion long alleles [22]. Individuals with the low expression
short (S) allele of the 5HTTLPR report significantly more
depressive symptoms when exposed to recent SLEs or
childhood maltreatment relative to those with the long (L)
allele (see [25] but also [26,27] for contradictory findings).
Similar findings have also been reported between the
5HTTLPR, childhood maltreatment and anxiety sensitiv-
ity, a risk factor for anxiety disorders [28]. Other studies
have shown replicated findings between variants in the
hypothalamic-pituitary-adrenal axis related genes (e.g.
FKBP5, [29,30]; CRHR1, [31]; NR3C1, [32]) and neuro-
trophic genes (e.g. BDNF val66met [33,34]) and mood and
anxiety disorders.
Diathesis-Stress and differential susceptibility
Gene-environment interaction research has typically been
couched in a diathesis-stress framework [35]. This frame-
work proposes that some individuals due to a genetic vul-
nerability are disproportionately likely to be adversely
impacted by an environmental stressor (e.g. SLEs, child-
hood maltreatment, insensitive parenting) compared to
individuals carrying the “protective” genotype. The conse-
quences being that those individuals carrying the “risk”
genotype are more likely to develop a psychological illness
when exposed to an adverse environment.
Some authors have argued that while diathesis-stress
phenomena are an incontestable characteristic of human
functioning and development, the situation is more
nuanced than that suggested by this framework [36]. G×E
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environments, predominantly emphasizing adverse envir-
onments and the impact for negative psychological
outcomes. Very few studies have measured positive envir-
onmental variables (aside from the absence of adversity) or
considered the effects for adaptive functioning and out-
comes (aside from the absence of dysfunction) [36].
The differential-susceptibility hypothesis [36-38] and
biological sensitivity to context framework [39] argue that
“vulnerability” genes may be a misnomer. Instead those
individuals considered “vulnerable” by virtue of their gen-
etic make-up and thus most adversely affected by negative
environments may in fact benefit the most from enriched
and supportive environments. In this way, individual dif-
ferences in developmental plasticity and susceptibility to
environmental influences may result in genetic influences
that act in a “for better and for worse” manner [37]. Some
individuals are more likely to be affected than others by
both negative and positive environmental conditions. Data
from quite a number of studies investigating a range of
markers (e.g. MAOA, 5HTTLPR, DRD2, DRD4, DAT1,
TPH1, HT2RA) have shown that individuals carrying the
putative “risk allele” do show a for better and for worse
pattern, functioning most poorly when exposed to nega-
tive environments but showing least problems when they
encounter the absence of adversity or positive environ-
ments (see [36] for a review).
Therapeutic GxE: genetic predictors of response
to treatment
The interaction between a therapeutic intervention and
genotype represents a special case of G×E [7]. Examining
a positive experience within a gene-environment inter-
action framework is rare. The use of a therapeutic inter-
vention, particularly a psychological intervention such as
CBT is an unusually powerful G×E design. The “environ-
ment” is positive and predictable, thus allowing any poten-
tial moderating genetic effects to be investigated
prospectively (unlike typical G×E designs where SLEs/mal-
treatment are unpredictable and commonly assessed
retrospectively). Furthermore, it enables consideration of
vulnerability markers that reflect differential susceptibility
to the environment, be it positive or negative. By using
“experimental manipulation” of G×E interactions, it is eas-
ier to rule out alternative explanations in terms of evoca-
tive or passive G×E correlations [40].
As an environmental factor, CBT and other psycho-
logical treatment interventions are likely to have a large
and potentially long-standing impact. CBT is a learning-
based intervention in which patients actively recall,
reappraise and reconstruct their cognitions and beha-
viours. It leads to symptom reductions and changes in
cognitions and behaviour (e.g. [41,42]) and there is some
evidence that CBT also alters neural function with thechanges consistent with the reduction in symptoms seen
following treatment (see [43]). There is preliminary evi-
dence that CBT may also stimulate structural brain
changes [44]. While not yet investigated in the context of
psychological treatments, it is plausible that the mechan-
isms of action for CBT may also include changes in gene
expression and neurogenesis as has been observed for
antidepressants [45,46].
Genetic predictors of response to pharmacological treat-
ments (pharmacogenetics) for mood and anxiety disorders
have been widely investigated using both candidate gene
and genome-wide (GWAS) methodologies. Some evidence
suggests that variants implicated in the pathogenesis of
the disorder may also predict response to antidepressants
[47]. For example, response to selective serotonin reuptake
inhibitors (SSRIs) but not tricyclic antidepressants is pre-
dicted by the presence of one or more copies of the high
expression L allele of the 5HTTLPR [48]. However, this as-
sociation has failed to replicate in several large studies
and overall a meta-analysis reported a nonsignificant effect
[49]. Genome wide studies have also identified plausible
candidate genes [50-52]. Currently, the strength of find-
ings from pharmacogenetics studies and the lack of repli-
cation mean that genetic associations are not yet
sufficiently strong or reliable to guide stratified treatment
selection [53].
Very few studies have investigated genetic predictors of
individual differences in response to psychological or psy-
chosocial interventions, a field we recently termed “thera-
pygenetics” [10]. Early work in this field focused on family
interventions and outcomes in child samples e.g. [40,54]
and produced findings consistent with a differential sus-
ceptibility framework in which the same genetic variant
operated in a for better and for worse manner [55]. More
recent work has investigated genetic predictors of re-
sponse to psychological treatment interventions, with the
majority of studies to date focusing on mood and anxiety
disorders.
Therapygenetics studies in mood and anxiety
disorders
Literature search methodology
Key word searches were performed in Web of Knowledge
using the following terms: “therapygenetics”; “genetics”
and “cognitive behavior therapy” and “response”; “genes”
and “psychotherapy”. Search results were reviewed for po-
tentially relevant empirical papers and 13 relevant papers
were identified, which had investigated genetic predictors
of response to a psychological intervention. Of those, 10
had mood or anxiety as the main disorder of interest and
the remainder focused on an alternative psychiatric dis-
order and are not reviewed here. Four studies on mood
and anxiety disorders were not yet indexed in Web of
Knowledge or had only been presented in (non-indexed)
Table 1 Summary of studies investigating associations between genetic variation and response to psychological
therapy in mood and anxiety disorders
Authors Diagnosis Sample Treatment Results
5HTTLPR/rs25531
Wang
et al. [58]
PTSD N = 35 12wk prolonged exposure therapy
or 12 wk Escitalopram (N = 20)
No significant association with treatment response in
exposure therapy group
Bryant
et al. [56]
PTSD N = 45, Caucasian, 8 × 90 min weekly individual CBT No significant association at post-treatment. At 6mth
follow-up, higher % of S i allele than L allele carriers met
PTSD criteria and had significantly higher symptom scoresMage = ~ 43 yrs, 33% female
Lonsdorf
et al. [59]
PD ± AG N = 69, Caucasian, 10 × 2 hr weekly group (N = 38)
or internet-delivered (N = 31)
CBT
No significant association with treatment response
Mage = ~ 35 yrs, 62% female
Furmark
et al. [60]
SAD N = 204, Mage = 38 yrs, 9 wk internet delivered CBT or
waitlist control
No significant association with treatment response
60% female
Kohen
et al. [61]
DEP
(post- stroke)
N = 61, mixed ethnicity 9 × positive problem solving
plus antidepressant vs. usual
care plus antidepressant
SS and SL carriers had a significantly greater mean
percentage reduction in depression ratings and more
likely to be in remission at 9-week follow-up than those in
the control group
Sakolsky
et al. [62]
SEP; GAD;
SAD
N = 211, Caucasian, Sertraline, 14 sessions of CBT,
combination therapy or 12 wk
placebo
No significant association with treatment response
7-17 yrs,
Eley et al.
[10]
ANX N = 359, Caucasian, 10-12 session group or
individual CBT or guided self-
help
No significant association at post treatment. At follow-up,
higher % of SS genotype carriers free of anxiety diagnoses
than SL/LL genotype carriers. SS genotype carriers had
significantly greater reduction in symptom severity scores
Mage = 9.44 yrs, 49% female
Hedman
et al. [63]
SAD N = 126, 98% Caucasian,
Mage = ~ 35 yrs, 36% female
15 × 2.5 hr weekly group (N = 62)
or internet-delivered (N = 64) CBT
No significant association with treatment response
Bockting
et al. [64]
Recurrent
DEP
N = 180, Caucasian, Brief CBT vs. treatment as usual No significant association with time to recurrence
Mage = 45 yrs, 74% female
STin2 VNTR
Kohen
et al. [61]
DEP
(post- stroke)
N = 64, mixed ethnicity 9 × positive problem solving
plus antidepressant vs. usual
care plus antidepressant
9/12 and 12/12 genotype carriers in intervention group had
a significantly greater mean percentage reduction in
depression scores and greater likelihood of remission at 9 wk
follow-up than controls
Sakolsky
et al. [62]
SEP; GAD;
SAD
N = 211, Caucasian, Sertraline, 14 sessions of CBT,
combination therapy or 12 wk
placebo
At 12-week assessment STin2 12-copy variant carriers
showed significantly greater improvement.
7-17 yrs
HTR2A rs7997012
Kotte
et al. [65]
DEP N = 58, 100% male 16-wk group CBT G allele predicted significantly larger reduction in BDI
scores across treatment compared to A allele carriers
TPH2 G-703T
Furmark
et al. [60]
SAD N = 204,
Mage = 38 yrs,
9 wk internet delivered CBT or
waitlist control
In the CBT group, a better treatment response was observed
in TPH2 GG homozygotes relative to T allele carriers
60% female
MAOA-u VNTR
Reif et al.
[66]
PD + AG N = 288, Caucasian 12 × twice weekly CBT Carriers of the long, higher activity alleleii had significantly
worse treatment outcome, elevated heart rate, greater fear
and panic attacks during a behavioral avoidance task and
failure to habituate during repetitive exposure
COMT val158met
Lonsdorf
et al. [59]
PD ± AG N = 69, Caucasian, 10 × 2 hr weekly group (N = 38)
or internet-delivered (N = 31)
CBT
No significant effect of COMTval158met genotype on
change in anxiety or depression scores across cognitive
modules (weeks 1-3). met/met genotype carriers had
significantly smaller reduction in anxiety scores across
exposure modules (weeks 4-9) compared to val-carriers
Mage = ~ 35 yrs, 62% female
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Table 1 Summary of studies investigating associations between genetic variation and response to psychological
therapy in mood and anxiety disorders (Continued)
Hedman
et al. [63]
SAD N = 126, 98% Caucasian,
Mage = ~ 35 yrs, 36% female
15 × 2.5 hr weekly group (N = 62)
or internet-delivered (N = 64) CBT
No significant association with treatment response
NGF rs6330
Lester
et al. [57]
ANX N =374, Caucasian, 10-12 session group or individual
CBT or guided self-help
No significant association with treatment response at post
treatment. At follow-up, children with one or more copies
of T allele of NGF rs6330 were significantly more likely to
be free of anxiety diagnosis
Mage = 9.46 yrs, 49% female
BDNF val66met; rs7934165; rs1519480;
rs11030104
Sakolsky
et al. [67]
SEP; GAD;
SAD
N = 211, Caucasian, Sertraline, 14 sessions of CBT,
combination therapy or 12 wk
placebo
No significant association with treatment response
7-17 yrs
Lester
et al. [57]
ANX N = 374, Caucasian, 10-12 session group or individual
CBT or guided self-help
No significant association with treatment response
Mage = 9.46 yrs, 49% female
Hedman
et al. [63]
SAD N = 126, 98% Caucasian,
Mage = ~ 35 yrs, 36% female
15 × 2.5 hr weekly group (N = 62)
or internet-delivered (N = 64) CBT
No significant association with treatment response
Fullana
et al. [68]
OCD N = 106, Caucasian, 20 × 45 min weekly exposure
based CBT plus SSRI
Met allele carriers significantly less likely to respond to
treatment than non-met allele carriers. Genotype
predicted response only and not change in severity scoresMage = 33 yrs, 50% female
GRIN2B rs1019385
Sakolsky
et al. [67]
SEP; GAD;
SAD
N = 211, Caucasian, Sertraline, 14 sessions of CBT,
combination therapy or 12 wk
placebo
No significant association with treatment response
7-17 yrs
GRIK4 rs1954787
Sakolsky
et al. [67]
SEP; GAD;
SAD
N = 211, Caucasian, Sertraline, 14 sessions of CBT,
combination therapy or 12 wk
placebo
Significant association with treatment
response at 12 week assessment
7-17 yrs
PTSD = post-traumatic stress disorder; PD ±AG = panic disorder with or without agoraphobia; SAD = social anxiety disorder; DEP = depression; SEP = separation
anxiety disorder, GAD = generalized anxiety disorder; ANX = all anxiety disorders; OCD = obsessive compulsive disorder.
I S allele group defined as SASA, SALA, SALG, SGLG, LALG, LGLG and L allele group defined as LALA.
ii Long, high activity risk allele group defined as 3.5, 4 and 5 copy
repeat allele males, and 2/4, 3/4, 3.5/4, 4/4, and 4/5 copy repeat allele females. Short, low activity allele group defined as 2 or 3 copy repeat allele males and 2/2,
2/3 and 3/3 females.
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sion by the authors. Six additional studies were identified
by inspection of reference lists of included studies and
relevant review articles. However, as these focused on
other psychiatric disorders or response to family-based
interventions with children and adolescents, these studies
are not considered further.Mood and anxiety disorders
Table 1 summarises the therapygenetics studies published
to date, where clinically diagnosed anxiety or depression
are the disorder phenotype of interest. The field is in its
infancy and this is reflected in the small, highly heteroge-
neous and preliminary nature of the existing literature. In
particular, sample sizes have ranged from very small pilot
studies (e.g. N = 45, [56]) to somewhat larger investiga-
tions (e.g. N = 374, [57]). However, modest sample sizes
mean the vast majority of studies are underpowered to de-
tect what we expect to be small genetic effects. Presently,
this limits our ability to draw strong conclusions regardingthe predictive ability of genetic variants for psychological
treatment response.
Studies thus far have relied on a candidate gene ap-
proach, testing the effect of a single marker or limited
number of genetic polymorphisms within a gene on psy-
chological treatment response. The most widely assessed
polymorphism has been the 5HTTLPR. In the following
section, we briefly outline the rationale for each genetic
marker being a plausible candidate for involvement in
psychological treatment response. We then review the
findings of therapygenetics studies to date, grouped by
the markers that have been considered. In light of the
infancy of the therapygenetics field, we then draw atten-
tion to several methodological issues for consideration
in future research.
Serotonin transporter linked polymorphic region (5HTTLPR)
Serotonergic neurotransmission is associated with anxiety
and mood disorders and is implicated in the treatment of
both types of disorder. By far the most widely studied
polymorphism has been the 5HTTLPR, which is a 43 bp
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moter region of the SLC6A4 gene, resulting in short and
long alleles, which differ in 5-HTT expression and func-
tion. The short allele variant is associated with approxi-
mately 50% less 5-HTT expression and function leading
to higher concentrations of serotonin in the synaptic cleft
[69]. The 5HTTLPR is often studied in conjunction with
the A/G single nucleotide polymorphism (SNP) rs25531,
which has been shown to differentially impact the L allele
function. The minor G allele is commonly in phase with
the long allele of the 5HTTLPR with the LG allele reported
to have transcriptional activity similar to the S allele [70].
Participants are often classified on the basis of presumed ef-
ficacy of serotonergic neurotransmission into low (SS, SLG,
or LGLG), intermediate (SLA or LALG) and high (LALA).
The evidence for an association between the 5HTTLPR
and mood and anxiety disorders has been somewhat
mixed. The low expression allele has most often been
associated with greater affective and anxiety-related traits
(e.g. [71-73]) and related intermediate phenotypes (e.g. at-
tentional bias to emotional stimuli [74]; fear conditioning
[75,76]; amygdala reactivity [77]). Consistent with the dif-
ferential susceptibility hypothesis, a recent meta-analysis
showed that the low expression allele was associated with
poorer outcomes following stress ([25], but see also [27]
for nonsignificant effects) but also appears to be associated
with better outcomes under low stress or positive environ-
ments [36]. This led to the hypothesis that the low expres-
sion S allele would be associated with enhanced response
to psychological therapies [10].
Nine studies have tested for an association between the
5HTTLPR and response to psychological therapy with
three studies reporting evidence of a significant associ-
ation. With respect to the five negative studies, there was
no significant association between the 5HTTLPR and re-
lapse rates following a course of CBT in remitted recur-
rently depressed adults (N = 180, [64]); improvement in
symptoms in response to internet based CBT for socially
anxious adults (N = 204, [60]; N = 126, [63]); improve-
ment in anxiety symptom scores in response to exposure
based CBT in panic disorder patients (N = 69, [59]) and
improvement in symptoms in response to multimodal
treatment in child anxiety disorders (N = 211, [62]). All of
these studies have small samples and are therefore under-
powered to detect what are very likely to be small genetic
effect sizes.
With regard to positive studies, anxiety-disordered
children (N = 359) carrying the low expression (SS) geno-
type were significantly more likely than the intermediate
(SL)/high (LL) expression genotype carriers to be free of
their anxiety disorder diagnosis (78.4% vs. 58.4%) and to
have a larger reduction in symptom severity scores after a
course of CBT or guided self-help [10]. In the second posi-
tive study (N = 61), the low expression (SS) genotype wasassociated with a greater percentage change in depression
scores in clinically depressed older adults after ischemic
stroke and in response to a brief problem solving plus
antidepressant intervention [61]. These findings appear
consistent with a differential susceptibility explanation in
which the same genetic variant, the low expression S al-
lele, which in prior studies has been associated with
increased risk for anxiety and depression, is also associated
with the most improvement in response to a positive psy-
chological treatment environment.
In contrast to the direction of effect observed in the two
previous studies [10,61], a third study found that the low
expression genotype was associated with more severe
PTSD symptoms and therefore fewer treatment gains at
6-months in patients undergoing exposure-based CBT for
PTSD (N = 45; [56]). In this study, the authors suggest
that the low expression allele may limit the capacity to
gain control over the anxiety elicited through CBT as a
consequence of greater amygdala reactivity, stronger fear
conditioning and deficits in extinction learning [56]. These
findings are also consistent with past (albeit mixed) re-
search reporting an association between the low expres-
sion genotype and poorer response to SSRIs [78]. In
a further study, PTSD patients received a 12-week
trial of citalopram (N = 20) or prolonged exposure therapy
(N = 15, [58]). The low expression SS genotype was again
associated with a poorer treatment response in both treat-
ment groups with the effect only attaining statistical sig-
nificance in the pharmacotherapy group [58]. The
contradictory findings observed for 5HTTLPR may reflect
not only small sample sizes and varying clinical pheno-
types, but also the role of medication. Further adequately
powered studies are required to clarify the association be-
tween 5HTTLPR and response to psychological treatment.
Serotonin transporter intron 2 variable number tandem
repeat (STin2 VNTR)
The STin2 VNTR of the 5-HTT gene has multiple
repeated copies of a 16-17bp element [79]. Nine (STin2.9),
ten (STin2.10) and 12 (STin2.12) repeat alleles have been
identified. Different copy number variations of the VNTR
have been shown to have differential regulatory effects on
transcription [80,81]. The short variant (9 or 10 repeats) is
associated with lower levels of 5-HTT mRNA and has
been linked with unipolar depression [82] and anxiety
[83]. However, others have reported an association be-
tween STin2.12 alleles and neuroticism [84] and anxiety
disorders [85].
Variation in STin2 has been examined in two therapyge-
netics studies. In the first, post-stroke depressed patients
with 9/12 or 12/12 repeat alleles showed a larger percent-
age reduction in depression scores to a problem-solving
intervention (N = 64, [61]). Similar significant associations
with treatment response were reported in a second study
Lester and Eley Biology of Mood & Anxiety Disorders 2013, 3:4 Page 7 of 16
http://www.biolmoodanxietydisord.com/content/3/1/4of children with a diagnosis of separation anxiety disorder,
generalized anxiety disorder or social phobia receiving ei-
ther sertraline medication, CBT or a combination therapy
(N = 211, [62]). Significantly greater improvement defined
by Clinical Global Impression-Improvement scores of very
much or much improved at post-treatment was observed
in carriers of the 12-copy variant after controlling for age
and treatment condition. The findings from these two
studies are in contrast to those reported in some studies
for response to SSRIs. For example, poorer remission
rates from major depression were reported in carriers of
the 12/12 genotype in the Sequenced Treatment Alterna-
tives to Relieve Depression study (STAR*D [86]).5-hydroxytryptamine (serotonin) receptor 2A gene (HTR2A)
The HTR2A gene encodes for 5-hydroxytryptamine 2A
receptors, which have been implicated in animal and
human models of depression and are thought to play an
important role in antidepressant drug action [87]. Several
polymorphisms in this gene have been studied in relation
to mood and anxiety disorders although associations
have tended to be small and findings have been mixed
[88,89]. The most widely studied polymorphisms have
been A-1438G (rs6311); C102T (rs6313) and His452Tyr
(rs6314). There is some evidence that genetic variants in
the HTR2A gene may predict differences in response to
SSRI treatment [87,90]. For example, a further SNP,
rs7997012, located in intron 2 of the HTR2A gene has
been associated with treatment response to antidepres-
sants in the STAR*D sample in both a discovery and repli-
cation sample. Being homozygote for the A allele was
associated with a 16-18% reduction in risk of non-
response compared to GG homozygote carriers [87,90].
A single therapygenetics study has tested for an associ-
ation between the HTR2A rs7997012 polymorphism and
response to a 16-week course of CBT in a sample of 58
male veterans experiencing unipolar depression [65]. In
contrast to the STAR*D studies investigating associa-
tions with antidepressant response, preliminary findings
showed that carriers of the G allele had a significantly
larger reduction in depression symptom scores in re-
sponse to CBT treatment than AA homozygotes.
Tryptophan hydroxylase 2 gene (TPH2)
The neuronal isoform of the TPH2 gene is expressed ex-
clusively within the nervous system and codes for the
rate-limiting enzyme for 5-HT biosynthesis in midbrain
and serotonergic neurons [91]. TPH2 has previously been
associated with depression [92] and anxiety disorders [93],
although findings have not always replicated. The SNP
G-703T (rs4570625) is located in the promoter region of
the TPH2 gene. It is thought to play a functional role in
regulating 5HT signaling and has a significant effect ongene expression with the T allele associated with reduced
transcriptional activity [94] and increased amygdala re-
activity to emotional stimuli [95,96].
A single therapygenetics study has tested for an associ-
ation between the TPH2 G-703T polymorphism and re-
sponse to a 9-week internet-based CBT intervention for
social anxiety disorder (N = 204, [60]). A significantly
greater improvement in self-report social anxiety symp-
tom scores was observed in GG homozygote individuals
compared to T allele carriers at post-treatment. Interest-
ingly, in an earlier paper the GG genotype significantly
predicted greater improvement in social anxiety symptoms
in response to a placebo drug condition [95]. Statistical
analyses were consistent with the improved treatment re-
sponse in GG genotype carriers being mediated by its ef-
fect on attenuating amygdala activity. This suggests a
possible biological mechanism linking genetically con-
trolled serotonergic modulation of amygdala reactivity and
treatment response. One might anticipate a similar medi-
ation mechanism linking TPH2 polymorphism and CBT
response given that placebo treatments are thought to act
on essentially the same neural pathways as those influ-
enced by active treatments [97,98]. This association with
placebo response also raises the interesting possibility that
the G-703T GG genotype may not be specifically asso-
ciated with therapeutic responsiveness but rather a more
general tendency to recover irrespective of treatment. This
can be best clarified further by the inclusion of a no treat-
ment control group alongside active and placebo treat-
ment conditions.
Monoamine oxidase-A variable number tandem repeat
(MAOA-u VNTR)
MAOA is a logical candidate gene for involvement in
psychiatric disorders due to its role in metabolizing sero-
tonin and norepinephrine [99]. A 30 bp VNTR poly-
morphism called MAOA-uVNTR in the promoter region
of the gene has recently been studied with regard to
psychological treatment response. This VNTR has a long
allele (3.5, 4 and 5 repeats) and short allele (2 and 3
repeats). The long alleles demonstrate increased transcrip-
tional activity [100,101] with levels of 5-hydrocyindoleacetic
acid (5-HIAA), the main metabolite of serotonin influenced
by this polymorphism [102]. The MAOA-uVNTR is often
referred to as the warrior-worrier gene [103] due to short-
allele repeats being associated with impulsive-aggressive be-
havior in males [21,104,105]. Long repeat alleles have been
associated with panic disorder in females [100,106] and
heightened sensitivity to aversive experiences [107].
Only one therapygenetics study has explored variation
in the MAOA-u VNTR [66]. In a sample of 288 patients
diagnosed with panic disorder with agoraphobia and re-
ceiving exposure-based CBT, carriers of the long repeat
higher activity risk allele had a significantly worse
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carriers of the short repeat allele (67% responders) [66]. In
response to a behavioural avoidance test involving enter-
ing a small dark chamber, L allele carriers experienced sig-
nificantly higher heart-rate during anticipation of the task,
as well as during exposure and recovery phases, more in-
tense anxiety during exposure, a greater frequency of
panic attacks and a failure to habituate. The authors argue
that the poorer outcome seen in L allele carriers is consist-
ent with a possible effect ofMAOA on the efficiency of ex-
tinction learning via decreased noradrenergic availability
[66]. This would be consistent with evidence that adrener-
gic enhancers facilitate exposure based CBT for anxiety
disorders (e.g. [108]).Catechol-O-methyltransferase gene (COMT)
Catechol-O-methyltransferase is a methylation enzyme
encoded by the COMT gene that acts to degrade monoa-
minergic neurotransmitters (e.g. dopamine, epinephrine,
norepinephrine) [109]. An A/G SNP, COMTval158met
(rs4680) codes for a valine (val) to methionine (met) ex-
change at position 158. The val allele is associated with
a three to four-fold increase in functional activity of the
methylation enzyme compared to the met allele, which
impacts on the degradation of dopamine and leads to an
excess of synaptic dopamine in met carriers [110,111].
Associations have been reported between the COMT-
val158met polymorphism and fear extinction processes
(for a review see [19]) and psychopathology, although
the direction of effects has not proven entirely consist-
ent. While COMT genotype was not found to be asso-
ciated with indices of fear conditioning [75,112], there
was some evidence that the met allele was associated
with stronger and extinction-resistant fear memories
using a 24-hour delayed extinction paradigm [75]. How-
ever, there was no significant association with extinction
learning in a further study using an immediate extinc-
tion procedure [112]. The val/val genotype has also been
associated with enhanced fear reacquisition under cer-
tain experimental conditions [76]. With regard to psy-
chopathology, the met allele has also been associated with
severity of PTSD [113], and phobic avoidance and panic
attacks in adolescent females [114]. However, the val allele
has also been associated with panic disorder [115].
Two therapygenetics studies have tested for an associ-
ation between the COMT gene and psychological treat-
ment response. Building on experimental studies of fear
conditioning and extinction, the COMTval158met was
considered for association with efficacy of group or
internet-delivered exposure-based CBT in a sample of
69 panic disorder patients [59]. No significant associ-
ation with genotype was observed for change in depres-
sion symptom scores across treatment or for change inanxiety symptom scores across the cognitive treatment
modules, which occurred early in treatment. However,
met/met genotype carriers reported a significantly smal-
ler reduction in anxiety symptoms across the exposure
treatment modules compared to val carriers. This effect
remained significant even after controlling for demo-
graphic and clinical variables and 5HTTLPR/rs25531
genotype. The authors suggest that impaired top-down
cognitive control over emotional reactions and a related
failure to extinguish fear reactions may represent one
pathway via which the met/met group gains less benefit
from psychological therapy [59]. In the only other thera-
pygenetics study to investigate the COMTval158met, no
significant association with response to group or internet
delivered CBT was observed in a sample of 126 patients
diagnosed with social anxiety disorder [63]. It is possible
that differences in disorder phenotype (e.g. PTSD vs.
SAD) may account for the discrepancy in findings or
that COMT genotype may be of greater relevance when
treatment modality is predominantly exposure based ra-
ther than cognitive based. Further research is needed to
test these hypotheses.Nerve growth factor (NGF)
A number of therapygenetics studies have focused on
candidate genes that are purportedly implicated in the
pathophysiology of learning with the rationale being that
CBT, and exposure based CBT especially rely on the
basic principles of extinction learning [116]. NGF is a
neurotrophic gene that is thought to have a key role in
neuronal survival, activity-dependent neuroplasticity and
learning, is implicated in the orchestration of response
to stress and is widely expressed in limbic areas of
the central nervous system involved in mood and cogni-
tion [117]. In NGF, rs6330 has been investigated as a
predictor of response to psychological therapy. This
non-synonymous SNP produces an alanine to valine
substitution at amino acid position 35 and is thought to
have a possible functional role on intracellular proces-
sing and secretion of NGF [118]. Allelic variation at this
locus has shown associations with anxiety-related traits
and affective disorders [119,120].
Variation in NGF rs6330 has been examined in a single
therapygenetics study to date. Likelihood of remission
increased with each extra T allele of the NGF rs6330 mar-
ker in a sample of anxiety-disordered children after a
course of CBT or guided self-help (N = 384, [57]). Fifty-
three percent of CC genotype carriers were free of their
primary anxiety diagnosis compared to 63.5% and 76.7%
for CT and TT genotypes respectively. However, the effect
of genotype was observed only at follow-up assessment
and not immediately post-treatment. One possibility is
that the NGF T allele may influence capacity for continued
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the T allele may show subtle differences in neurotrophic
signalling that influence the extent to which environmental
influences, in this instance therapeutic interventions bring
about neuroplastic modifications, which in turn modulate
mood [57].
Brain-derived neurotrophic factor gene (BDNF)
BDNF, like NGF is also a neurotrophic gene. BDNF se-
cretion is activity dependent with decreases associated
with stress, mood disorders and anxiety-related behav-
iour and increases with antidepressant medication [121].
The most frequently studied polymorphism in the BDNF
gene has been the functional val66met (rs6265) poly-
morphism. In val66met, the more common G allele
encodes for valine (val) with the A allele encoding for me-
thionine (met). The met allele is associated with dimin-
ished activity-dependent secretion of BDNF [122,123],
abnormalities in brain structure and function in limbic
regions [124-126]. The val66met polymorphism has also
been studied in conjunction with associative fear learning,
fear generalisation and extinction processes, albeit with
mixed findings (for a review see [19]).
Four therapygenetics studies have tested for an associ-
ation between the BDNF gene and psychological treatment
response. The most frequently studied polymorphism has
been the val66met (rs6265) polymorphism, however other
polymorphisms within this gene have also received atten-
tion (rs7934165, rs1519480, rs11030104). Three studies
failed to find any association between BDNF variants
and response to psychotherapy for child anxiety disorders
(N = 374, [57]); response to multimodal treatment for
child anxiety disorders (N = 211, [67]) or adult social
anxiety disorder treated with group or internet-based CBT
(N = 126, [63]). However, a single study reported an associ-
ation between the val66met polymorphism and response
to exposure-based CBT in a sample of 106 OCD patients
who had previously shown partial or non-response to a 12-
week pharmacological trial [68]. Thirty-six percent of met
allele carriers compared to 60% of val carriers responded
to treatment defined as a 35% or greater decrease in Yale-
Brown Obsessive Compulsive Scale scores. Of note, all par-
ticipants also received concurrent SSRI treatment in this
study and the treatment modality was predominantly ex-
posure based rather than cognitive based. While warrant-
ing further investigation, these methodological differences
may in part account for the discrepancy with other studies.
Glutamate receptor, ionotropic N-methyl D-asparate 2B
gene (GRIN2B)
The GRIN2B gene encodes the NR2 subunit of the N-me-
thyl-D-aspartate (NMDA) glutamate receptors, which are
important for fear acquisition and fear consolidation [127]
and learning and memory more broadly [128]. The SNP,rs1019385 located in NMDA 2 beta subunit is a promoter
region variant in which the G allele leads to reduced tran-
scriptional activity which in turn may affect glutamate
neurotransmission [129]. GRIN2B has been associated with
childhood OCD [130], and related biological traits includ-
ing reduced anterior cingulate glutamatergic concentration
[131]. However, in the only therapygenetics study to type
this marker there was no significant association
between GRIN2B rs1019385 and response to CBT, pharma-
cotherapy or combined treatment defined by improvement
scores in a sample of children with anxiety diagnoses (N =
213, [67]). Note, however, that no children with a primary
OCD diagnosis were included in this sample.
Glutamate receptor, ionotropic kainite 4 gene (GRIK4)
The GRIK4 gene encodes for a kainate preferring ionotro-
pic glutamate receptor subtype involved in modulating
neurotransmitter release and excitatory neurotransmis-
sion. The SNP, rs1954787 located in the 3’ end of the first
intron is not thought to alter protein sequence but may
have functional relevance via regulation of gene expression
[90]. A recent study reported an association between the
C allele of this marker and improved treatment response
to antidepressants in the STAR*D cohort [90] but this ef-
fect did not replicate in the Munich Antidepressant Re-
sponse Signature sample after correction for the number
of SNPs tested [132]. This marker has been investigated in
one therapygenetics study to date. A significant associ-
ation between the rs1954787 SNP and treatment response
defined as a rating of very much or much improved on
the Clinician Global Impression – Improvement scale was
observed after controlling for age, treatment condition
and other genetic polymorphisms investigated in a sample
of children with anxiety diagnoses (N = 213, [67]). How-
ever, it is unclear whether GRIK4 genotype interacts with
treatment type as some children received medication,
others CBT and some a combined therapy.
Methodological considerations
A small number of studies have provided preliminary but
provocative evidence in support of an association between
genetic polymorphisms and response to psychological
therapy. Independent replication of these early findings in
adequately powered samples should be a priority. Several
other studies have failed to find any evidence for a signifi-
cant association or have produced conflicting results. In
this section we outline some of the methodological issues
and directions for future research, which we believe
should be considered in future therapygenetics research.Sample characteristics
Therapygenetics studies have been conducted with child,
adult and older adult samples. At this stage, no particular
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psychological treatment response may be more or less
likely to be observed in younger versus older samples.
However, developmental factors are an important consid-
eration. Twin studies have identified that genetic and en-
vironmental influences on depression change across
adolescence (e.g. [133]). It is therefore plausible that new
or different genetic effects or environmental experiences
may emerge at different points across development and
which may be instrumental in determining psychological
treatment response. Other participant characteristics, for
example, gender, socio-economic status, educational levels
and motivation may also interact with genetic factors to
influence psychological treatment response. Consideration
of the ethnic background of the sample is also very im-
portant for genetic association studies. Thus far, most
therapygenetics studies have employed samples with pre-
dominantly Caucasian ancestry. The use of ancestrally
homogenous samples or appropriate statistical techniques
(e.g. principal components approaches) to control for an-
cestral heterogeneity is very important as by doing so any
risk associated with hidden population substructures lead-
ing to spurious results is attenuated.
Treatment characteristics
In therapygenetic studies conducted to date, the psycho-
logical treatment variable has not been consistent. Mul-
tiple CBT treatment formats have been used, which differ
with respect to aspects such as whether the treatment was
delivered face to face or over the internet, in an individual
or group format, predominantly cognitive or exposure
based in focus, the “dose” of treatment delivered and
whether parents were involved in the treatment process.
CBT is also a multimodal treatment combining a variety
of cognitive and behavioural components. Some authors
have suggested that genetic variants might have greater
predictive power for more focused psychological treat-
ments [134]. Inspection of the present findings does not
reveal any particularly strong and compelling pattern of
effects. Ultimately, if genetic predictors are to be useful
clinically then any predictive effects would need to rise
above this noise.
Several of the studies reviewed also included participants
who received a combined treatment comprising both psy-
chological therapy and medication (e.g. [61-63,67,68]). This
raises an interpretive challenge as it becomes difficult to
disentangle which component of treatment is associated
with any genetic predictive effects. Combined treatment
approaches may also mask and reduce any potential pre-
dictive effects of genetic variants for response to psycho-
logical therapy.
The majority of studies to date have not included a no-
treatment control group. The advantage of such a group
would be to distinguish between association with recoverytime per se and recovery following psychological treatment.
Where genes predict response in the active treatment but
not no-treatment control group it would be possible to
conclude with greater certainty that any genetic effects
observed were specifically predictive of therapeutic re-
sponse and not just a general tendency toward improve-
ment across time. The use of wait list control groups are
sufficient to test this hypothesis with respect to genetic
associations with response immediately post-treatment.
However, the withholding of a broadly efficacious interven-
tion for the extended period of time needed to test this hy-
pothesis with respect to genetic associations at a follow-up
assessment cannot be easily justified for ethical reasons.
Disorder characteristics
Accurate and reliable characterisation of the disorder
phenotype will continue to be important. We advocate
the use of semi-structured diagnostic interviews and clin-
ician scored rating scales as these provide an objective
measure of diagnosis, functioning and clinical improve-
ment. Self-report scales have a number of methodological
challenges (e.g. biases in reporting), which may potentially
lead to an inaccurate reporting of symptoms [135]. How
treatment response is defined is also important. Some
studies have defined positive treatment response in terms
of remission of the primary diagnosis, others in terms of
cut-offs based on percentage reduction in symptom sever-
ity scores, some have looked at raw symptom scores and
finally a small number of studies have investigated related
phenotypes including time to recurrence. As the field pro-
gresses it will be important for some consistency to
emerge with respect to defining response. This is particu-
larly important because to amass the large sample sizes
necessary to achieve sufficient power to reliably detect
genetic effects will require collaboration amongst research
teams. This inevitably brings with it problems in ensuring
that the treatment and clinical measures are sufficiently
similar to permit the combination of samples. The selec-
tion of appropriate measures should perhaps be guided by
what is most clinically meaningful. Our recommendations
would be remission of the primary diagnosis of interest
and ratings of improvement using the Clinician Global
Impression Improvement scale.
Molecular genetic and statistical considerations
Studies so far have focused on a small number of pre-
dominantly functional candidate markers in a limited
number of genes. Immediate efforts should be directed
toward attempting replication of the most promising
findings published to date using adequately powered
samples. In selecting targets for future candidate gene
studies it has been suggested that a focus on variants
implicated in the etiology of the disorder may prove to
be the most robust predictors of response [7,8].
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in etiology are also likely to prove important. With in-
creasing sample sizes we anticipate that studies may move
away from candidate gene approaches to hypothesis free
genome wide association designs in conjunction with gen-
ome wide complex-trait analysis methods [136]. However,
perhaps as a caution it is noteworthy that GWAS studies
have yet to report replicated SNPs associated with anti-
depressant response for depression (see [50-52]). Integrat-
ing genotype information with epigenetic and gene
expression data and with neurophysiological, psycho-
logical and behavioural measures may prove important in
terms of identifying possible biological and psychological
mechanisms that mediate the effect of genetic variants on
psychological treatment response.
Given that psychological treatment response, like anx-
iety and depressive disorders is a complex trait, it is un-
likely that any single gene in isolation will explain a
sufficiently large amount of the variance in response to
psychotherapy to be clinically meaningful in its own
right (although with a sufficient sample size even very
weak predictive effects may obtain statistical signifi-
cance). Sample sizes to date have been relatively small
which will have limited power to observe statistically sig-
nificant effects. Even the largest study to date only had a
total sample size of 374 [57]. It has been suggested that
effects explaining as little as 1% of the variance should
be considered important [137] - the NGF rs6330 poly-
morphism accounted for 2.3% of the variance in treat-
ment outcome. This is a relatively encouraging effect
size given that gene-environment interactions are often
modest in size and represent a substantial methodo-
logical challenge in terms of requiring relatively large
samples to obtain sufficient statistical power and careful
and accurate measurement of treatment outcome.
However, it is widely reported that new association find-
ings tend to overestimate the true size of the effect due
to a phenomenon known as the winner’s curse [138].
This overestimation in initial studies can cause replica-
tion studies to fail due to them being underpowered.
However, independent replication studies and at a later
stage, meta-analyses are essential if the field of therapy-
genetics is to progress and yield potentially clinically
useful applications.
Future directions
At present, genetic predictors do not have sufficient pre-
dictive power to warrant their use as a clinical bio-
marker. Moving toward analytic methods that aggregate
across multiple polymorphisms and/or genes into a sin-
gle parameter in combination with machine learning
methods may be the most powerful means of achieving
clinically significant prediction and building toward a
stratified medicine approach for mood and anxietydisorders [134,139]. Combining genetic information with
clinical and demographic predictors [140] or perhaps
with neuroimaging biomarkers [141] within a single al-
gorithm may also prove to be a particularly powerful ap-
proach. More broadly, the inclusion of clinical covariates
within models designed to test association between spe-
cific SNPs and psychological treatment outcome is im-
portant. Clinical predictors such as baseline symptom
severity, the presence of comorbid disorders and familial
history of illness are themselves likely to be under gen-
etic influence. It is therefore important to show that any
predictive effect of a genetic variant exists above and be-
yond the effect of any significant clinical predictors.
For an individual patient, the key clinical decision is
not whether to treat or not but instead which treatment
to select to maximize the chance of recovery [7]. In
these circumstances, using genetic markers to predict re-
sponse to a particular treatment is of limited clinical
utility. Instead, as a medium term aim, therapygenetics
studies need to move away from predicting response to
a single psychological treatment and instead should aim
to identify differential predictors of response to alterna-
tive treatment modalities. For example being able to esti-
mate on the basis of genetic information, the relative
likelihood of response to pharmacotherapy versus psy-
chotherapy would be of considerably greater clinical
value than identifying that a particular patient is more or
less likely to respond positively to SSRIs. However, it
may not be realistic to expect to find a genetic variant
associated with response to pharmacological treatment
per se given the different biological pathways via which
different classes of drugs exert their influence. One way
to progress might be to try and identify genetic variants
that differentially predict response to a specific psycho-
logical therapy e.g. CBT compared to response to a spe-
cific class of drugs e.g. SSRIs or MAOIs. Unreplicated
research suggests an interesting potential double dissoci-
ation between 5HTTLPR genotype and response to
SSRIs and CBT treatment modalities. In adult depres-
sion, response to SSRIs has been shown to better in LL
carriers of the 5HTTLPR [47], while some therapyge-
netics studies have observed better response to CBT in
SS carriers [10,61]. However, it is important to note
that several studies failed to find any association be-
tween 5HTTLPR and response to psychological therapy
[58-60,62-64], while one study reported that SS carriers
did in fact have fewer positive treatment gains [56],
which would argue against a dissociation relative to
pharmacological findings. Studies are required in which
patients are randomly assigned to pharmacotherapy or
CBT to fully test this hypothesis. One possibility is that
interactions with environmental variables and differing
etiological pathways into and out of mood and anxiety dis-
orders may partly account for these differential findings.
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interplay (e.g. with SLEs and early developmental
experiences such as maltreatment) in predicting treat-
ment outcome for psychological therapies. This would
require large samples due to testing mutually dependent
influences of multiple factors and accurate and in-depth
characterization of environmental exposure history,
ideally both negative and positive environmental expo-
sures, treatment outcomes and the collection of genetic
material [7]. Despite these methodological challenges,
we believe that this would be a promising line of re-
search, although it is unclear at this stage whether G×E
interactions will have sufficient predictive value to guide
personalized treatment decisions. Two recent studies
identified that carriers of the SS genotype of the
5HTTLPR responded poorly to SSRI treatment but this
association was only observed in those who experienced
a stressful life event prior to treatment [142,143]. These
findings are consistent with a combination of stress and
greater genetic risk to stress predicting poorer response.
However, this finding did not replicate in a third study
[144]. While as yet untested and in contrast to findings
from antidepressant studies, one possibility is that
increased genetic vulnerability to stress (e.g. presence of
the 5HTTLPR SS genotype) in combination with the
presence of a stressful life event may in fact be asso-
ciated with a better response to psychological therapies.
In the antidepressant literature, significant G×E interac-
tions have been reported between exposure to SLEs
and SNPs in FKBP5 (rs1360780) and CRHR1 (rs110402)
(see [18] for a review). However, here a combination of
exposure to life stress and presence of the putative risk
allele predicted a better treatment response. As sug-
gested by others, disentangling the etiological pathways
to mood and anxiety disorders may make it possible to
differentially predict which individuals are at an
increased likelihood of responding to pharmacological
or psychotherapeutic interventions [18].
Conclusions
Genes, environments, and gene-environment interac-
tions contribute causally to mood and anxiety disorders.
In this article, we have considered the evidence for
genetic factors also being implicated in predicting indi-
vidual variation in response to psychological treatment
interventions. Therapygenetics, the study of genetic pre-
dictors of response to psychological therapy is a field
very much in its infancy. Early findings have been some-
what mixed but several studies have provided promising
evidence that individuals respond differently to psycho-
logical interventions and that genetic differences are
capable of predicting differential susceptibility to psy-
chotherapy. These findings show that interactions be-
tween genetic variation and environmental experiences(here, psychological therapy) may not only influence the
development but also the remission of psychiatric out-
comes. However, as yet these findings have not been in-
dependently replicated and the strength of findings are
not sufficient to suggest immediate practical applica-
tions. We have suggested several methodological factors
that warrant careful consideration in future research.
We would strongly encourage clinical researchers to in-
corporate the collection of a genetic sample into their
treatment protocols. Genetic variation can be measured
with little error and remains stable over time and it is
reasonable to hope that combining genetic information
with clinical and environmental information or other
biomarkers may prove to be particularly informative in
guiding treatment selection, improving outcome and
providing a better understanding of psychopathology.
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